The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reading Rheum

Reading Rheum

August 1, 2007 • By Robyn Domsic, MD; David G. Borenstein, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

LUPUS

Rituximab for Neuropsychiatric Lupus

By Robyn Domsic, MD

You Might Also Like
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum
Explore This Issue
August 2007

Tokunaga M, Saito K, Daisuke Kawabata D, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66(4):470-475.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Abstract

Aim: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious treatment-resistant phenotype of systemic lupus erythematosus. A standard treatment for NPSLE is not available. This report describes the clinical and laboratory tests of 10 patients with NPSLE before and after rituximab treatment, including changes in lymphocyte phenotypes.

Methods: Rituximab was administered at different doses in 10 patients with refractory NPSLE, despite intensive treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: Treatment with rituximab resulted in rapid improvement of central nervous system (CNS)–related manifestations, particularly acute confusional state. Rituximab also improved cognitive dysfunction, psychosis, and seizure, and reduced the SLE Disease Activity Index Score at day 28 in all 10 patients. These effects lasted for more than one year in five patients. Flow cytometric analysis showed that rituximab down-regulated CD40 and CD80 on B cells and CD40L, CD69, and inducible costimulator on CD4+ T cells.

Conclusions: Rituximab rapidly improved refractory NPSLE, as evident by resolution of various clinical signs and symptoms and improvement of radiographic findings. The down-regulation of functional molecules on B and T cells suggests that rituximab modulates the interaction of activated B and T cells through costimulatory molecules. These results warrant further analysis of rituximab as treatment for NPSLE.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE
click for large version

Commentary

This study is the first case series reporting the outcomes with rituximab for CNS manifestations of lupus. Prior series have included patients with CNS involvement as one of their lupus manifestations, but improvement in CNS symptoms has not been the focus of these studies and received little more than a few sentences in the discussion. Interestingly, this article received the fourth highest number of hits in the month of April on the Annals of Rheumatic Disease Web site. This is not surprising since the use of rituximab in the treatment of rheumatic disease, particularly lupus, is a hot topic.

From the abstract, the study sounded convincing and I was excited about the use of rituximab for CNS lupus. Once I delved into the methods section, however, concerns began to arise. Allow me to review the inclusion criteria of the study: 1) highly active disease and 2) CNS lesions resistant to conventional treatment. If the latter criterion is strictly followed, then it is not clear how one individual with a headache and normal MRI and a second with mood disorder and a normal MRI qualify as two of the ten patients.

Pages: 1 2 3 4 | Single Page

Filed Under: Research Reviews Tagged With: Back pain, Literature, LupusIssue: August 2007

You Might Also Like:
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum
  • Reading Rheum: Lumbar Spinal Stenosis

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.